Dr. Reddy’s Laboratories Announces Launch of the Sputnik V vaccine in the Indian Market
Hyderabad, India. May 14, 2021 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY. NSEIFSC: DRREDDY, hereafter referred to as ”Dr. Reddy’s”) today announced that the first consignment of imported doses of the Sputnik V vaccine that landed ill India on 1st May, 2021. received regulatory clearance from the Central Drugs Laboratory, Kasauli, on 13th May. 2021. As part of a limited pilot, the soft launch of the vaccine has commenced and the first dose of the vaccine was administered in Hyderabad today on 14th May 2021.
Further consignments of imported doses are expected over the upcoming months. Subsequently, supply of the Sputnik V vaccine we commence from Indian manufacturing partners. The imported doses of the vaccine are presently priced at an MRP of As 948 + 5% GST per dose, with the possibility of a lower price Point when local supply begins. The Company is working closely with its six manufacturing partners in India to fulfill regulatory requirements to ensure smooth and timely supply.
Dr. Reddy’s will work closely with stakeholders in the Government and private sector in India to ensure the widest possible reach of the Sputnik V vaccine as pan of the national inoculation effort. This is a reaffirmation of the Company’s commitment to explore every avenue in the fight against the COVID-19 pandemic in India.
G V Prasad, Co-Chairman and Managing Director, said: ”With the rising cases in India. vaccination is our most effective tool in our battle against COVID-19. Contributing to the vaccination drive in India is our biggest priority right now to help Indians be healthy and safe.”
